Mounjaro, manufactured by Lilly, may have emerged as the newest and most effective treatment option after a victory over Novo Nordisk’s Ozempic in clinical trials. For some patients, injectables ...
The shortage, which began in December 2022 for Mounjaro and extended to Zepbound in April 2023, led to a surge in demand for compounded versions of the drugs. But with tirzepatide removed from the ...